| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,413,000 |
| Market
Cap: |
8.95(B) |
| Last
Volume: |
591,041 |
Avg
Vol: |
504,733 |
| 52
Week Range: |
$114.17 - $208.42 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$238,260 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
23,589 |
45,669 |
50,307 |
151,828 |
| Total Sell Value |
$4,058,631 |
$8,416,817 |
$9,119,818 |
$30,980,273 |
| Total People Sold |
2 |
4 |
5 |
6 |
| Total Sell Transactions |
2 |
5 |
7 |
17 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Snodgres Jon |
Chief Financial Officer |
• – – |
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
900 |
30,793 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2022-02-17 |
4 |
D |
$182.42 |
$31,924 |
D/D |
(175) |
17,184 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
450 |
17,359 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2022-02-17 |
4 |
D |
$182.42 |
$60,928 |
D/D |
(334) |
6,890 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
900 |
7,224 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2022-02-17 |
4 |
D |
$182.42 |
$40,862 |
D/D |
(224) |
33,544 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
450 |
33,768 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2021-12-14 |
4 |
D |
$252.53 |
$112,376 |
D/D |
(445) |
16,909 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2021-11-18 |
4 |
AS |
$273.91 |
$4,804,674 |
D/D |
(17,355) |
182,140 |
|
-33% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2021-11-18 |
4 |
OE |
$32.40 |
$324,000 |
D/D |
10,000 |
199,495 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2021-11-10 |
4 |
AS |
$259.75 |
$1,262,355 |
D/D |
(4,783) |
91,247 |
|
-32% |
|
| Dawes Karen A |
Director |
– • – |
2021-11-10 |
4 |
OE |
$26.12 |
$124,932 |
D/D |
4,783 |
96,030 |
|
- |
|
| Ryan Thomas F Jr |
Director |
– • – |
2021-11-04 |
4 |
S |
$288.00 |
$288,000 |
D/D |
(1,000) |
12,337 |
|
31% |
|
| Ryan Thomas F Jr |
Director |
– • – |
2021-11-02 |
4 |
S |
$302.00 |
$388,070 |
D/D |
(1,285) |
13,337 |
|
41% |
|
| Ryan Thomas F Jr |
Director |
– • – |
2021-11-02 |
4 |
OE |
$128.18 |
$164,711 |
D/D |
1,285 |
14,622 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2021-11-02 |
4 |
AS |
$299.02 |
$729,467 |
D/D |
(2,400) |
91,247 |
|
-41% |
|
| Barthelemy Nicholas |
Director |
– • – |
2021-10-29 |
4 |
S |
$288.19 |
$474,085 |
D/D |
(1,645) |
1,547 |
|
43% |
|
| Barthelemy Nicholas |
Director |
– • – |
2021-10-29 |
4 |
OE |
$128.18 |
$164,711 |
D/D |
1,285 |
3,192 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2021-09-14 |
4 |
AS |
$290.02 |
$80,628 |
D/D |
(274) |
93,647 |
|
-37% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2021-09-09 |
4 |
AS |
$294.22 |
$7,368,650 |
D/D |
(25,000) |
189,495 |
|
-36% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2021-09-09 |
4 |
OE |
$32.40 |
$810,000 |
D/D |
25,000 |
214,495 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2021-09-01 |
4 |
S |
$285.33 |
$963,559 |
D/D |
(3,377) |
33,318 |
|
26% |
|
| Dawes Karen A |
Director |
– • – |
2021-09-01 |
4 |
AS |
$280.27 |
$982,058 |
D/D |
(3,459) |
93,921 |
|
-26% |
|
| Dawes Karen A |
Director |
– • – |
2021-09-01 |
4 |
OE |
$38.76 |
$134,071 |
D/D |
3,459 |
97,380 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2021-08-30 |
4 |
S |
$282.13 |
$1,128,802 |
D/D |
(4,001) |
17,354 |
|
26% |
|
647 Records found
|
|
Page 7 of 26 |
|
|
2.76 (1.86%) 
